Publications by authors named "K V Savostyanov"
The 5q Spinal Muscular Atrophy (SMA) is a hereditary autosomal recessive disease caused by defects in the survival motor neuron () gene encoding survival motor neuron (SMN) protein. Currently, it is the leading cause of infantile mortality worldwide. SMA is a progressive neurodegenerative disease with "continuum of clinical severity", which can be modulated by genetic and epigenetic factors known as disease modifiers (DMs).
View Article and Find Full Text PDFThe scratch test is used as an experimental in vitro model of mechanical damage to primary neuronal cultures to study the mechanisms of cell death in damaged areas. The involvement of NMDA receptors in processes leading to delayed neuronal death, due to calcium dysregulation and synchronous mitochondrial depolarization, has been previously demonstrated. In this study, we explored the neuroregenerative potential of Pro-Gly-Pro (PGP)-an endogenous regulatory peptide with neuroprotective and anti-inflammatory properties and a mild chemoattractant effect.
View Article and Find Full Text PDFArticle Synopsis
- Stem cell technology is pivotal in regenerative medicine, utilizing stem/progenitor cells for repairing or replacing damaged tissues to treat various diseases like cardiovascular and neurological disorders.
- Cell therapy works through two main mechanisms: the replacement of damaged tissue and the release of biologically active molecules that aid in tissue regeneration, but challenges like transportation complexity and immune rejection exist.
- The study focuses on the beneficial effects of proteins secreted by glial progenitor cells, showing they can reduce inflammation and support neuron survival by inhibiting harmful factors and maintaining cellular health, potentially paving the way for new therapeutic applications.
Article Synopsis
- The study investigates the safety and effectiveness of canakinumab for patients with undifferentiated autoinflammatory diseases (uAIDs), which had not been previously assessed.
- Data from 32 uAID patients were analyzed, revealing a range of symptoms and prior treatments before starting canakinumab, including fever, rash, and various organ involvements.
- Results showed that 84% of patients achieved complete remission, while a smaller percentage had partial or no response to the treatment.
Background: Fabry disease (FD) is a rare hereditary multisystem disease caused by variants of the gene. Determination of gene variants and identification of genotype-phenotype correlations allow us to explain the features of FD associated with predominant damage of one or another system, both in the classical and atypical forms of FD, as well as in cases with late manifestation and involvement of one of the systems.
Methods: The study included 293 Russian patients with pathogenic variants of the gene, which were identified as a result of various selective screening programs.